Brain insulin resistance: A treatment target for cognitive impairment and anhedonia in depression
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
&NA; Type 2 Diabetes Mellitus (T2DM) and Major Depressive Disorder (MDD) are leading causes of disability worldwide. Indeed, both are costly and burdensome diseases at both individual and socio‐economic levels. Notably, there are similar pathophysiological elements, which might explain the overlap in phenotypic symptoms and the high rate of comorbidity. Brain insulin resistance is a shared metabolic abnormality amongst many individuals with T2DM and MDD. Patients with either or both diseases often exhibit disturbances in cognition and mood, as well as the presence of anhedonia‐like symptoms. However, individuals with T2DM with high glycemic control have reduced cognitive and depressive symptom burden. Based on this evidence, it is possible that repurposing therapies approved for treating insulin resistance may be useful in treating cognitive and anhedonia symptoms in depression. The objective of this review is to discuss the relationship between brain insulin resistance and depression, as well as possible disease modifying therapeutic agents targeting insulin signalling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“Glucagon-like peptide I (GLP-I) is a gut derived incretin that is beneficial in glycemic control and helps improve insulin sensitivity while reducing appetite and food intake (Drucker and Nauck, 2006; Gault et al., 2013).”
BackgroundRole of Brain Insulin Receptor in Control of Body Weight and Reproduction
Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Müller-Wieland, D., & Kahn, C. R. (2000) · Science · doi:10.1126/science.289.5487.2122 · Cited by 2,235
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
Aguirre, V., Werner, E. D., Giraud, J., Lee, Y. H., Shoelson, S. E., & White, M. F. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m101521200 · Cited by 1,010
Self-citationExercise as a treatment for depression: A meta-analysis
Kvam, S., Kleppe, C. L., Nordhus, I. H., & Hovland, A. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.03.063 · Cited by 837
Exercise for the treatment of depression and anxiety
Carek, P. J., Laibstain, S. E., & Carek, S. M. (2011) · The International Journal of Psychiatry in Medicine · doi:10.2190/pm.41.1.c · Cited by 797 · cited 1×
“Therefore exercise may be implemented as both a preventative measure for depression and as a therapeutic agent (Carek et al., 2011).”
BackgroundTreatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
The role of insulin receptor signaling in the brain
Plum, L., Schubert, M., & Brüning, J. C. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.01.008 · Cited by 604
Exercise and the Prevention of Depression: Results of the HUNT Cohort Study
Harvey, S. B., Øverland, S., Hatch, S. L., Wessely, S., Mykletun, A., & Hotopf, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16111223 · Cited by 493
The source of cerebral insulin
Banks, W. A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.040 · Cited by 489 · cited 1×
“Insulin can also cross the blood brain barrier (BBB) via a saturable transporter, suggesting insulin in the brain may originate from both brain and pancreatic sources (Banks et al., 2012; Butterfield et al., 2014; Werner and LeRoith, 2014; Banks, 2004).”
BackgroundCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Exercise and insulin resistance in type 2 diabetes mellitus: A systematic review and meta-analysis
Sampath Kumar, A., Maiya, A. G., Shastry, B. A., Vaishali, K., Ravishankar, N., Hazari, A., Gundmi, S., & Jadhav, R. (2019) · Annals of Physical and Rehabilitation Medicine · doi:10.1016/j.rehab.2018.11.001 · Cited by 469
Localization of insulin receptor mRNA in rat brain by in situ hybridization
MARKS, J. L., PORTE, D., STAHL, W. L., & BASKIN, D. G. (1990) · Endocrinology · doi:10.1210/endo-127-6-3234 · Cited by 448 · cited 1×
“Insulin receptors are found throughout the brain (both neurons and glia) with the highest expression found in regions regulating autonomic activity, appetite, and olfaction as well as emotional and cognitive function (Havrankova et al., 1978; Werther et al., 1987; Marks et al., 1990).”
BackgroundDepression in type 2 diabetes mellitus: prevalence, impact, and treatment
Semenkovich, K., Brown, M. E., Svrakic, D. M., & Lustman, P. J. (2015) · Drugs · doi:10.1007/s40265-015-0347-4 · Cited by 447
Mannan, M., Mamun, A., Doi, S., & Clavarino, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157240 · Cited by 421 · cited 1×
“A recent meta-analysis suggests that depressed individuals have a 70% increased risk of obesity, and those who are obese have a 40% increased risk of depression, suggesting there is convergence of depression, insulin resistance and reward-seeking behaviour (Mannan et al., 2016).”
BackgroundButterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402
Intranasal Treatment of Central Nervous System Dysfunction in Humans
Chapman, C. D., Frey, W. H., Craft, S., Danielyan, L., Hallschmid, M., Schiöth, H. B., & Benedict, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0915-1 · Cited by 310
Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity
Grillo, C. A., Piroli, G. G., Lawrence, R. C., Wrighten, S. A., Green, A. J., Wilson, S. P., Sakai, R. R., Kelly, S. J., Wilson, M. A., Mott, D. D., et al. (2015) · Diabetes · doi:10.2337/db15-0596 · Cited by 308
Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart
Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H. L., Born, J., & Kern, W. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301193 · Cited by 302
Cognitive Impairment in Bipolar Disorder: Treatment and Prevention Strategies
Solé, B., Jiménez, E., Torrent, C., Reinares, M., Bonnin, C. D. M., Torres, I., Varo, C., Grande, I., Valls, E., Salagre, E., et al. (2017) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx032 · Cited by 299
The interface of depression and obesity
Jantaratnotai, N., Mosikanon, K., Lee, Y., & McIntyre, R. S. (2017) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2016.07.003 · Cited by 282
Self-citationShould Depressive Syndromes Be Reclassified as “Metabolic Syndrome Type II”?
McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., Woldeyohannes, H. O., Law, C. W. Y., Miranda, A., Fulgosi, D., & Kennedy, S. H. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701653377 · Cited by 277
Self-citationSa-nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.08.005 · Cited by 274
Haroon, E., Fleischer, C. C., Felger, J. C., Chen, X., Woolwine, B. J., Patel, T., Hu, X. P., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.206 · Cited by 250
Marks, D. R., Tucker, K., Cavallin, M. A., Mast, T. G., & Fadool, D. A. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.1350-09.2009 · Cited by 242 · cited 6×
“Intranasal administration allows for a non-invasive, direct delivery of insulin to the brain, bypassing the BBB and thereby avoiding potential systemic side effects of lowering blood glucose levels (Born et al., 2002; Chapman et al., 2013).”
BackgroundInfluentialClaxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
Abdul‐Ghani, M. A., Puckett, C., Triplitt, C., Maggs, D., Adams, J., Cersosimo, E., & DeFronzo, R. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12417 · Cited by 208
Insulin Regulates Brain Function, but How Does It Get There?
Gray, S. M., Meijer, R. I., & Barrett, E. J. (2014) · Diabetes · doi:10.2337/db14-0340 · Cited by 206 · cited 1×
“However, insulin is a critically important neuropeptide needed for cognitive functioning as well as other neurotrophic, neuromodulatory and neuroprotective processes (Blázquez et al., 2014; Gray et al., 2014).”
BackgroundPipatpiboon, N., Pintana, H., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12088 · Cited by 183 · cited 2×
“(Sa-Nguanmoo et al., 2017; Pintana et al., 2016; Pipatpiboon et al., 2013; Pintana et al., 2013) Mansur and colleagues demonstrated an association with a GLP-I receptor agonist and improved executive functioning as well as increased gray matter volume in brain regions subserving cognition for…”
BackgroundZhang, H., Hao, Y., Manor, B., Novak, P., Milberg, W., Zhang, J., Fang, J., & Novak, V. (2015) · Diabetes · doi:10.2337/db14-1000 · Cited by 176
McIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145
Self-citationMetformin and ageing: improving ageing outcomes beyond glycaemic control
Valencia, W. M., Palacio, A., Tamariz, L., & Florez, H. (2017) · Diabetologia · doi:10.1007/s00125-017-4349-5 · Cited by 142
Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.512046 · Cited by 123 · cited 1×
“Glucagon-like peptide I (GLP-I) is a gut derived incretin that is beneficial in glycemic control and helps improve insulin sensitivity while reducing appetite and food intake (Drucker and Nauck, 2006; Gault et al., 2013).”
BackgroundMcIntyre, R. S., Powell, A. M., Kaidanovich-Beilin, O., Soczynska, J. K., Alsuwaidan, M., Woldeyohannes, H. O., Kim, A. S., & Gallaugher, L. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.021 · Cited by 110
Self-citationKemp, D. E., Ismail-Beigi, F., Ganocy, S. J., Conroy, C., Gao, K., Obral, S., Fein, E., Findling, R. L., & Calabrese, J. R. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.06.033 · Cited by 109
McIntyre, R. S., Soczynska, J. K., Woldeyohannes, H. O., Miranda, A., Vaccarino, A., MacQueen, G., Lewis, G. F., & Kennedy, S. H. (2012) · Bipolar Disorders · doi:10.1111/bdi.12006 · Cited by 104
Self-citationA Neural Circuitry Linking Insulin Resistance to Depressed Mood
Ryan, J. P., Sheu, L. K., Critchley, H. D., & Gianaros, P. J. (2012) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31824d0865 · Cited by 68
Determinants of cognitive function in individuals with type 2 diabetes mellitus: a meta-analysis
Mansur, R. B., Lee, Y., Zhou, A. J., Carmona, N. E., Cha, D. S., Rosenblat, J. D., Bruins, R., Kakar, R., Rasgon, N. L., Lovshin, J. A., et al. (2018) · Annals of Clinical Psychiatry · doi:10.1177/154733251803000107 · Cited by 64
Self-citation
Cited by
The menace of obesity to depression and anxiety prevalence
Fulton, S., Décarie-Spain, L., Fioramonti, X., Guiard, B., & Nakajima, S. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.10.005 · Cited by 441
“In turn, a high percentage of patients with depression exhibit insulin resistance [124].”
BackgroundThe brain as an insulin-sensitive metabolic organ
Milstein, J. L., & Ferris, H. A. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101234 · Cited by 259
The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis
Chen, X., Zhao, P., Wang, W., Guo, L., & Pan, Q. (2024) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.08.010 · Cited by 185
Depression, antidepressants, and insulin resistance: which link?
Fanelli, G., & Serretti, A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.04.011 · Cited by 39
El Massry, M., Alaeddine, L. M., Ali, L., Saad, C., & Eid, A. A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200908114902 · Cited by 27
Metadata
- Authors
- Hamer, J. A., Testani, D., Mansur, R. B., Lee, Y., Subramaniapillai, M., & McIntyre, R. S.
- Venue
- Experimental Neurology
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 315
- Pages
- 1-8
- ISSN
- 0014-4886 (ISSN-L)
- OpenAlex
- W2912265551
- Cited by
- 136
- References
- 38
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.